Baltimore, MD
Peptide Therapy clinics in Baltimore
Baltimore has a Johns Hopkins-adjacent academic medicine culture and full NP practice authority, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across Harbor East, Mount Vernon, Towson, and Federal Hill range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Johns Hopkins, University of Maryland, and MedStar network. The scene here skews toward academic-affiliated physicians running longevity practices with conservative protocols. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Baltimore clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Baltimore HCG Therapy Clinic
- Peptide Therapy
- Testosterone Replacement Therapy (TRT)
- Hormone Replacement Therapy (HRT)
Weight-Loss Center
- Peptide Therapy
- Erectile Dysfunction (ED) Treatment
- Testosterone Replacement Therapy (TRT)
- Hormone Replacement Therapy (HRT)
BMore Hydrated
- NAD IV Therapy
- Vitamin IV Therapy
- IV Hydration
- Peptide Therapy
- Hormone Replacement Therapy (HRT)
Regulatory context
A note on Maryland's peptide therapy rules.
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. The FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list during 2023 and 2024, restricting 503A pharmacy sourcing. Section 503A covers traditional patient-specific compounding; Section 503B covers FDA-registered outsourcing facilities held to cGMP.
-
Maryland Pharmacy Act (Health Occupations Article Title 12)
Governs pharmacy licensure and compounding under the Maryland Board of Pharmacy. -
Maryland Medical Practice Act (Health Occupations Article Title 14)
Regulates physician prescribing and delegation. -
Maryland Naturopathic Doctor Act (Health Occupations Article Title 14 Subtitle 54)
Licenses NDs with a limited formulary that generally excludes routine injectable peptide prescribing.
The Maryland Board of Pharmacy inspects compounding facilities under USP 795 and USP 797 standards. Non-resident pharmacies shipping peptides into Maryland must hold a current waiver or permit. The Board coordinates with the FDA and neighboring jurisdictions (DC, Virginia) on cross-border enforcement. Disciplinary actions are published on the Board's website.